For Immediate Release --BIVDA, the UK’s national association for the manufacturers and distributors of in vitro (IVD) products, welcomes the adoption of amended transitional provisions of the In Vitro Diagnostic Medical Devices Regulation.This decision will allow for a more workable transition for IVD sector companies to prepare for transition into the new European regulatory framework for IVD medical tests.On 20th December, the European Council confirmed their support in full of the propo...

A new clinical validation study from Oulu University Hospital was recently published in a widespread international cancer journal, confirming that new-generation GastroPanel® test is highly accurate in diagnosing atrophic gastritis and Helicobacter pylori infection in gastroscopy referral patients

Life Science Group (LSG) has been shortlisted for a prestigious award which recognises and promotes the excellence that East and West Midlands companies are achieving at the leading edge of the Life Sciences sector

Semi-Quantitative COVID-19 IgG Antibody Rapid Test now available for use by professionals or trained lay-users

The European Stakeholder Group has issued a joint statement calling for clarity on the United Kingdom’s association to Horizon Europe as soon as possible. A formalisation of the UK's involvement and access to the Horizon Europe programme has not yet taken place following the UK's departure from the European Union.Horizon Europe is the EU’s key funding programme for research and innovation with a budget of €95.5 billion. It creates jobs, fully engages the EU’s talen...

BIOFORTUNA DOUBLE THEIR MANUFACTURING CAPACITY 1st November 2021 Biofortuna (Deeside UK), a specialist contract development and manufacturing partner to the IVD and point of care testing sectors, has more than doubled its manufacturing capacity following its relocation to new state-of-the-art facilities in Deeside, North Wales.The purpose-built facilities have been designed by the Company to provide the most efficient and modern manufacturing laboratories from which to meet the evolvin...

Press Release - BIVDA responds to the Government’s £248 million investment to modernise diagnostics -- Nearly £250 million is to be injected by the Government into the modernisation of diagnostic care across the NHS. This will lead to improved technology, data sharing, accelerate routine care and, crucially, help tackle significant care backlogs.  Delivering more diagnostic tests, health checks and scans is non-negotiable for the UK population’s health...

-- For Immediate Release BIVDA, the UK’s leading association for In Vitro Diagnostics (IVD) technology and innovation, responds to today’s Budget announcements, outlined in the House of Commons by Chancellor Rishi Sunak. This Budget comes at a crucial moment regarding protecting the UK’s health service through the winter as it tackles backlogs and readies itself for future public health threats. The Government must recognise the role of both the home-grown d...

For Immediate Release--- The British In Vitro Diagnostics Association is calling for this Spending Review to invest in key enablers to support the UK diagnostic sector’s capacity to tackle care backlogs, drive innovation and prepare for potential future pandemics. Building a diagnostics sector that is pandemic-ready and can support the UK’s healthcare needs requires stronger UK manufacturing, innovation, a highly skilled workforce and support for companies becoming more sustaina...

BIVDA is hosting its 2021 Mid-Year Meeting on Thursday 21 October, and the final agenda for the event has been published.  Please find the PDF agenda file for members below, you must register your attendance at our Eventbrite page here. MGM Agenda File.